.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
US Army
Healthtrust
UBS
Farmers Insurance
Novartis
Teva
Johnson and Johnson
Cipla
Medtronic

Generated: December 15, 2017

DrugPatentWatch Database Preview

MINOCIN Drug Profile

« Back to Dashboard

When do Minocin patents expire, and when can generic versions of Minocin launch?

Minocin is a drug marketed by Precision Dermat, Triax Pharms, Lederle, and Rempex Pharms Inc. and is included in five NDAs. There are two patents protecting this drug.

This drug has twenty-three patent family members in twenty countries.

The generic ingredient in MINOCIN is minocycline hydrochloride. There are thirteen drug master file entries for this compound. Fifty-four suppliers are listed for this compound. Additional details are available on the minocycline hydrochloride profile page.
Drug patent expirations by year for MINOCIN

Pharmacology for MINOCIN

Ingredient-typeTetracyclines
Drug ClassTetracycline-class Drug

Medical Subject Heading (MeSH) Categories for MINOCIN

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Precision DermatMINOCINminocycline hydrochlorideCAPSULE;ORAL050649-001May 31, 1990ABRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Rempex Pharms IncMINOCINminocycline hydrochlorideINJECTABLE;INJECTION050444-001Approved Prior to Jan 1, 1982RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Triax PharmsMINOCINminocycline hydrochlorideCAPSULE;ORAL050315-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Rempex Pharms IncMINOCINminocycline hydrochlorideINJECTABLE;INJECTION050444-001Approved Prior to Jan 1, 1982RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Precision DermatMINOCINminocycline hydrochlorideCAPSULE;ORAL050649-003Feb 12, 2001DISCNYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Precision DermatMINOCINminocycline hydrochlorideCAPSULE;ORAL050649-002May 31, 1990ABRXNoNo► Subscribe► Subscribe► Subscribe► Subscribe
LederleMINOCINminocycline hydrochlorideINJECTABLE;INJECTION062139-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Triax PharmsMINOCINminocycline hydrochlorideCAPSULE;ORAL050315-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
Precision DermatMINOCINminocycline hydrochlorideSUSPENSION;ORAL050445-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: MINOCIN

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,744,179Tetracycline compositions► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: MINOCIN

Country Document Number Estimated Expiration
Spain2613738► Subscribe
Poland2568987► Subscribe
European Patent Office2568987► Subscribe
Russian Federation2012147527► Subscribe
Australia2011252919► Subscribe
Portugal2568987► Subscribe
Japan2013529201► Subscribe
New Zealand707329► Subscribe
Hong Kong1180586► Subscribe
Denmark2568987► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Daiichi Sankyo
Baxter
US Army
Johnson and Johnson
Dow
McKinsey
McKesson
Chubb
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot